IL-4Rα Inhibitor for Atopic Disease.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 28708993.
- Also identified by DOI 10.1016/j.cell.2017.06.046.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Dupilumab is a fully human IgG4 monoclonal antibody directed against the IL-4Rα subunit of IL-4 and IL-13 receptors. It blocks the signaling pathways of IL-4 and IL-13, key cytokines that drive type 2 inflammatory response. In March 2017, dupilumab was approved for use in the treatment of atopic dermatitis (eczema). To view this Bench to Bedside, open or download the PDF.
Medical subject headings
- Antibodies, Monoclonal
- Dermatitis, Atopic